Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats - PubMed (original) (raw)

Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats

K Tsutsumi et al. Diabetes. 1995 Apr.

Abstract

We have previously reported that the novel compound NO-1886 increased lipoprotein lipase (LPL) activity, with resulting elevation of high-density lipoprotein (HDL) cholesterol in normal rats (J Clin Invest 92:411-417, 1993). The aim of this study was to ascertain whether the compound has the same action in diabetes, because hypertriglyceridemia with low HDL cholesterol is an extremely common concomitant condition in diabetes. Streptozotocin-induced diabetic rats showed marked elevation of plasma triglyceride and reduction of HDL cholesterol. Both single and repeated administration of NO-1886 increased postheparin plasma LPL activity, with resulting reduction of plasma triglyceride and elevation of HDL cholesterol. Repeated administration increased the amount of LPL mRNA in adipose tissue and myocardium. The compound had no effects on plasma glucose and insulin levels. Our study indicates that the compound is potentially beneficial for the treatment of hypertriglyceridemia with low HDL cholesterol in diabetes.

PubMed Disclaimer

Cited by

The Effects of Prolonged Treatment with Cemtirestat on Bone Parameters Reflecting Bone Quality in Non-Diabetic and Streptozotocin-Induced Diabetic Rats.
Martiniakova M, Kovacova V, Mondockova V, Svik K, Londzin P, Folwarczna J, Soltesova Prnova M, Stefek M, Omelka R. Martiniakova M, et al. Pharmaceuticals (Basel). 2023 Apr 21;16(4):628. doi: 10.3390/ph16040628. Pharmaceuticals (Basel). 2023. PMID: 37111385 Free PMC article.
Antihyperglycemic, antihyperlipidemic and hepatoprotective effects of Ficus ottoniifolia (Miq.) Miq. supplementation in alloxan-induced diabetic rats.
Aloke C, Nwachukwu N, Obasi NA, Emelike CU, Amu PA, Ogbu PN, Orinya OF, Ogbonnia EC. Aloke C, et al. Avicenna J Phytomed. 2021 Sep-Oct;11(5):428-435. doi: 10.22038/AJP.2020.16958. Avicenna J Phytomed. 2021. PMID: 34745915 Free PMC article.
Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.
Prnova MS, Kovacikova L, Svik K, Bezek S, Elmazoğlu Z, Karasu C, Stefek M. Prnova MS, et al. Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):651-661. doi: 10.1007/s00210-019-01769-1. Epub 2019 Dec 5. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 31802170
Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator.
Geldenhuys WJ, Caporoso J, Leeper TC, Lee YK, Lin L, Darvesh AS, Sadana P. Geldenhuys WJ, et al. Bioorg Med Chem Lett. 2017 Jan 15;27(2):303-308. doi: 10.1016/j.bmcl.2016.11.053. Epub 2016 Nov 21. Bioorg Med Chem Lett. 2017. PMID: 27913180 Free PMC article.
Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.
Geldenhuys WJ, Lin L, Darvesh AS, Sadana P. Geldenhuys WJ, et al. Drug Discov Today. 2017 Feb;22(2):352-365. doi: 10.1016/j.drudis.2016.10.007. Epub 2016 Oct 19. Drug Discov Today. 2017. PMID: 27771332 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats - PubMed (original) (raw)